- Home
- WCT vs TXMD Comparison
WCT vs TXMD Comparison
Compare WCT & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WCT
- TXMD
- Stock Information
- Founded
- WCT 2012
- TXMD 2008
- Country
- WCT Hong Kong
- TXMD United States
- Employees
- WCT N/A
- TXMD N/A
- Industry
- WCT
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- WCT
- TXMD Health Care
- Exchange
- WCT NYSE
- TXMD Nasdaq
- Market Cap
- WCT 9.7M
- TXMD 13.5M
- IPO Year
- WCT 2024
- TXMD N/A
- Fundamental
- Price
- WCT $0.22
- TXMD $1.17
- Analyst Decision
- WCT
- TXMD
- Analyst Count
- WCT 0
- TXMD 0
- Target Price
- WCT N/A
- TXMD N/A
- AVG Volume (30 Days)
- WCT 566.3K
- TXMD 35.2K
- Earning Date
- WCT 05-16-2025
- TXMD 08-11-2025
- Dividend Yield
- WCT N/A
- TXMD N/A
- EPS Growth
- WCT N/A
- TXMD N/A
- EPS
- WCT N/A
- TXMD N/A
- Revenue
- WCT $2,309,218.00
- TXMD $1,841,000.00
- Revenue This Year
- WCT N/A
- TXMD $427.09
- Revenue Next Year
- WCT N/A
- TXMD N/A
- P/E Ratio
- WCT N/A
- TXMD N/A
- Revenue Growth
- WCT N/A
- TXMD 53.55
- 52 Week Low
- WCT $0.12
- TXMD $0.70
- 52 Week High
- WCT $9.36
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- WCT N/A
- TXMD 47.76
- Support Level
- WCT N/A
- TXMD $1.13
- Resistance Level
- WCT N/A
- TXMD $1.24
- Average True Range (ATR)
- WCT 0.00
- TXMD 0.09
- MACD
- WCT 0.00
- TXMD 0.01
- Stochastic Oscillator
- WCT 0.00
- TXMD 73.12
About WCT WELLCHANGE HOLDINGS COMPANY LIMITED
Wellchange Holdings Co Ltd is an enterprise software solution services provider. It provides software solutions, cloud-based software-as-a-service (SaaS) platforms, and white-label software design and development services.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.